Giampaolo Bianchini· @BianchiniGP · X·· 22 小时前评分70
正文 · 原文
🔥 KEYNOTE-B49 meets its primary endpoint, but benefit seems limited to few patients
👉 ICIs benefit selected ER+/HER2− BC pts (CPS≥10, ER-low)
👉 Are ADCs better ICI partners than CT?
👉 What about PD-1/VEGF bispecifics?
➡️ Better biomarkers urgently needed!
#ESMO26
46 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Giampaolo Bianchini · x.com